TC
YARW

Truvestments Capital’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Truvestments Capital’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15 Hold
1
– – ﹤0.01% 1163
2025
Q4 		$15 Hold
1
– – ﹤0.01% 1023
2025
Q3 		$8 Hold
1
– – ﹤0.01% 1046
2025
Q2 		$41 Hold
1
– – ﹤0.01% 941
2025
Q1 		$40 Buy
+1
New +$123 ﹤0.01% 1011

Other funds holding YARW

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Truvestments Capital's YARW Position: Q1 2026 in Review

Truvestments Capital held its Yarrow Bioscience, Inc. Common Stock (YARW) position steady in Q1 2026 at 1 share worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #1163.

Truvestments Capital first reported a position in YARW in Q1 2025 and has held it in 5 quarters since. The position peaked at $41 in Q2 2025. 42 funds tracked by Wall St. Rank hold YARW as of Q1 2026.

  • Truvestments Capital held 1 share of Yarrow Bioscience, Inc. Common Stock worth $15 as of Q1 2026.
  • Truvestments Capital left its Yarrow Bioscience, Inc. Common Stock share count unchanged in Q1 2026.
  • Yarrow Bioscience, Inc. Common Stock made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #1163 holding.
  • Truvestments Capital first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2025 and has held it in 5 quarters since.
  • Truvestments Capital's Yarrow Bioscience, Inc. Common Stock position peaked at $41 in Q2 2025.
  • 42 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.